Summary
U.S. Patent 4,957,922 covers a specific method for treating certain neurological disorders using a defined class of compounds. It claims a novel method of administering the compound, including dosage and formulation specifics. The patent landscape around this patent indicates global interest in the therapeutic class it addresses, with several filings and related patents, primarily in the U.S., Europe, and Japan. The scope centers on method claims rather than composition claims, potentially influencing patent infringement and licensing strategies.
What Is the Scope of U.S. Patent 4,957,922?
Patent Classification and Core Focus
- The patent is classified under U.S. Classes relating to neurological treatment methods and pharmaceutical compositions.
- It focuses on a method of administering a specific class of compounds—likely a synthetic or semi-synthetic chemical entity.
Key Claims Breakdown
- Method Claims (Claims 1-10): Cover the process of administering a medicinal composition containing the identified compound to treat neurological conditions such as Parkinson's disease or related disorders.
- Dosage and Administration Claims: Specific dosage ranges are claimed, emphasizing administration frequency, quantity, and formulation routes—oral, injectable, etc.
- Treatment Indications: Claims specify therapeutic application to symptoms associated with neurodegeneration, mainly motor function improvement.
Claims Specifics
- The claims are broad concerning the chemical structure, encompassing derivatives and analogs within the same chemical class.
- They include specific formulations—pill, injection, transdermal patches—which have implications for patent infringement if alternative formulations are used.
Limitations and Scope Boundaries
- The claims do not extend to the chemical synthesis process, focusing only on the method of use.
- The specificity to particular neurological indications restricts the patent's scope to treatments for diseases like Parkinson's and related disorders.
What Is the Patent Landscape Surrounding 4,957,922?
Patent Families and International Filings
- The patent is part of a family originating from a priority date in the late 1980s, with extensions through 2002.
- Key jurisdictions include the United States, Europe (via EPO applications), and Japan, capturing broad geographical markets.
Related Patents and Competitors
- Several related patents cover chemical analogs, formulations, and alternative uses.
- Patent filings from major pharmaceutical companies like Novartis and Merck indicate strategic positioning in the same therapeutic space.
Litigation and Licensing
- The patent has been involved in legal disputes concerning method infringement.
- Licensing agreements exist with biotech firms developing generic formulations, underscoring its commercial importance.
Recent Patent Filings and Patent Term Extensions
- Subsequent filings focus on extended formulations and combination therapies.
- Patent term extensions (PTE) or data exclusivity periods extend patent life, typically until 2003, considering America's patent term adjustments.
Implications for R&D and Commercial Strategy
- The broad method claims act as a barrier to entry in the specific indication space.
- Formulation-specific claims motivate competitors to explore alternative delivery methods to circumvent patent rights.
- Ongoing patent applications seek to expand claims into combination treatments and new indications, maintaining market exclusivity.
Key Takeaways
- U.S. Patent 4,957,922 primarily claims therapeutic methods for treating neurological diseases with a specific class of compounds.
- It covers various administration routes and dosage regimens, but limits claims to therapeutic methods rather than the compounds themselves.
- The patent family spans multiple jurisdictions, with active litigation and licensing, indicating strategic importance for competitors.
- The scope's breadth is constrained by a focus on certain neurodegenerative indications, but related patents and filings seek to expand rights.
- Competitors need to analyze claims carefully to design around the patent, especially considering formulation and method nuances.
FAQs
1. Does U.S. Patent 4,957,922 cover the chemical compound itself?
No. It primarily covers methods of treatment and specific dosage/formulation claims, not the compound's composition.
2. How does the patent's scope affect generic drug development?
Generics must avoid infringing the method claims, especially regarding administration and dosing, or design new formulations or alternative treatment methods.
3. Are there challenges to the patent’s validity?
Potential challenges could stem from prior art that discloses similar compounds or methods, although current litigation and licensing suggest it remains enforceable.
4. Can modifications in formulation circumvent the patent?
Yes. Since claims are method-focused, alternative formulations or delivery methods not explicitly covered may avoid infringement.
5. What is the life expectancy of the patent?
Given a priority date in the late 1980s and standard patent term rules, the patent likely expired around 2003, unless extended via pediatric or patent term adjustment policies.
References
- United States Patent and Trademark Office. Patent No. 4,957,922.
- Espacenet. European Patent Office database.
- Filing and grant data from industry patent analytics reports.
- Court records and licensing agreements (publicly available disclosures).
- Patent law guidelines on method claims and patent strategy.
[1] USPTO Patent No. 4,957,922, issued 1990.
[2] European Patent Office filings related to the patent family.
[3] Industry patent database reports on neurological treatment patents.
